Medicus Pharma Ltd. Files 6-K with Q3 Financials
Ticker: MDCXW · Form: 6-K · Filed: Nov 25, 2024 · CIK: 1997296
Sentiment: neutral
Topics: financials, reporting, pharmaceuticals
TL;DR
Medicus Pharma dropped its Q3 financials on 11/25 - check the 6-K for details.
AI Summary
Medicus Pharma Ltd. filed a Form 6-K on November 25, 2024, reporting on its financial performance for the three and nine months ended September 30, 2024. The filing includes Management's Discussion and Analysis and Condensed Consolidated Interim Financial Statements. The company is incorporated in A6 and its fiscal year ends on December 31.
Why It Matters
This filing provides investors with updated financial statements and management's analysis, crucial for understanding the company's performance and making informed investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing (6-K) and does not contain new material events or significant financial changes.
Key Numbers
- 2834 — SIC Code (Indicates the company operates in the Pharmaceutical Preparations industry.)
Key Players & Entities
- Medicus Pharma Ltd. (company) — Registrant
- September 30, 2024 (date) — Reporting period end date
- November 25, 2024 (date) — Filing date
- 100 King Street West, Suite 3400, Toronto, Ontario, Canada, M5X 1A4 (address) — Principal executive office and mailing address
FAQ
What period does the financial information in this 6-K cover?
The financial information covers the three and nine months ended September 30, 2024.
When was this Form 6-K filed?
This Form 6-K was filed on November 25, 2024.
What are the key exhibits included in this filing?
The key exhibits are Exhibit 99.1 (Management's discussion and analysis) and Exhibit 99.2 (Condensed consolidated interim financial statements).
What is Medicus Pharma Ltd.'s fiscal year end?
Medicus Pharma Ltd.'s fiscal year ends on December 31.
Where is Medicus Pharma Ltd. headquartered?
Medicus Pharma Ltd.'s principal executive office is located at 100 King Street West, Suite 3400, Toronto, Ontario, Canada, M5X 1A4.
Filing Stats: 190 words · 1 min read · ~1 pages · Grade level 10.5 · Accepted 2024-11-25 08:00:16
Filing Documents
- form6k.htm (6-K) — 6KB
- exhibit99-1.htm (EX-99.1) — 143KB
- exhibit99-2.htm (EX-99.2) — 277KB
- 0001062993-24-019596.txt ( ) — 427KB
Management's discussion and analysis for the three and nine months ended September 30, 2024
Management's discussion and analysis for the three and nine months ended September 30, 2024 99.2 Condensed consolidated interim financial statements for the three and nine months ended September 30, 2024 and 2023
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Medicus Pharma Ltd. Date: November 25, 2024 By /s/ Raza Bokhari Name: Dr. Raza Bokhari Title: Executive Chairman and Chief Executive Officer